Mark Baxter

There's still about a non-response rate of about 10% to 20%.

So there's still people that aren't getting benefit for different reasons.

What we're seeing is something akin to that, but what we're doing, the work we're doing is seeing people in a real context.

So it's not just people who are chosen for a clinical trial.

So in clinical trials, a lot of people are rejected because of exclusion criteria.

Whereas in our clinical practice, we're including people because people need that help.

So we're seeing people with lots of comorbidities, lots of life stage dysregulation, lots of bits and pieces that regular people have.

Life is messy.

So we're getting all of that coming in, which is the work that we want to do and what we're welcoming.

And so it's a bit trickier for us and what we're looking at.

But we're seeing, you know, again, about two thirds of people that are getting some good benefits and a further third that maybe the treatment was not as effective as they'd hoped or maybe the treatment opened a little bit of a door and they need to persist with therapy for another couple of years to kind of work on that door that was opened.

And so...

Yeah.

Yeah.

Yeah.

just heard one the other day where a person that I was working on with a co-therapist of mine, you know, she's taking up yoga, she's doing singing classes, she's feeling free.

She's not, doesn't have the symptoms of PTSD like she did before.

And so this is a year on.

And like just after therapy, she was doing better, but she was still very much in it.

She had a great therapist that continued the treatment.